Bioinformatics Life Science Pharma Companies Vaccine 
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
XTalks
DECEMBER 13, 2023
These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 27, 2022
data processing systems that support bioinformatics modelling) and digital record systems (e.g. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. Digital technologies can cover a broad range of applications, and include mobile health (mHealth) tools (e.g.
Drug Discovery World
AUGUST 7, 2024
In the last year alone, AI has been used for identifying novel targets 1 in areas like cardiomyopathy, generating novel antibodies 2 , and even designing newer modalities 3 like optimised mRNA vaccines for influenza. Pharma R&D has been heading in the wrong direction, becoming progressively less efficient over the last few decades.
Drug Discovery World
JULY 19, 2023
Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science. What does open science look like?
Expert insights. Personalized for you.
96 
Let's personalize your content